Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Seres Therapeutics ( (MCRB) ) is now available.
On February 4, 2025, Seres Therapeutics expanded its Board of Directors to nine members and appointed Dr. Hans-Juergen Woerle as a Class III director. This appointment is linked to an agreement with Nestlé, which holds a significant stake in the company, granting them the right to designate a board member. Dr. Woerle, with extensive experience in medical and scientific roles, will contribute to Seres’ strategic direction, particularly in science and clinical development, enhancing the company’s industry positioning.
More about Seres Therapeutics
Seres Therapeutics, Inc. operates in the biotechnology industry, focusing on developing microbiome therapeutics. The company aims to innovate in the health sector by harnessing the microbiome’s potential to create groundbreaking treatments.
YTD Price Performance: -5.95%
Average Trading Volume: 2,671,890
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $135M
For an in-depth examination of MCRB stock, go to TipRanks’ Stock Analysis page.
